生长分化因子15是一种评估丙酮酸疗法对线粒体疾病疗效的新型生物标志物。
GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases.
作者信息
Fujita Yasunori, Ito Masafumi, Kojima Toshio, Yatsuga Shuichi, Koga Yasutoshi, Tanaka Masashi
机构信息
Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi, Tokyo 173-0015, Japan.
Health Support Center, Toyohashi University of Technology, 1-1 Hibarigaoka Tenpaku-cho, Toyohashi, Aichi 441-8580, Japan.
出版信息
Mitochondrion. 2015 Jan;20:34-42. doi: 10.1016/j.mito.2014.10.006. Epub 2014 Nov 1.
Pyruvate therapy is a promising approach for the treatment of mitochondrial diseases. To identify novel biomarkers for diagnosis and to evaluate therapeutic efficacy, we performed microarray analysis of 2SD cybrid cells harboring a MELAS-causing mutation and control cells treated with either lactate or pyruvate. We found that expression and secretion of growth differentiation factor 15 (GDF15) were increased in 2SD cells treated with lactate and that serum GDF15 levels were significantly higher in patients with mitochondrial diseases than in those with other diseases, suggesting that GDF15 could be a useful marker for diagnosis and evaluating the therapeutic efficacy of pyruvate.
丙酮酸疗法是一种很有前景的线粒体疾病治疗方法。为了鉴定用于诊断的新型生物标志物并评估治疗效果，我们对携带导致MELAS突变的2SD杂交细胞以及用乳酸或丙酮酸处理的对照细胞进行了微阵列分析。我们发现，用乳酸处理的2SD细胞中生长分化因子15（GDF15）的表达和分泌增加，并且线粒体疾病患者的血清GDF15水平显著高于其他疾病患者，这表明GDF15可能是诊断和评估丙酮酸治疗效果的有用标志物。
Zotero 插件